{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:07:41Z","timestamp":1784693261293,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.mcna.2021.04.001","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T12:19:31Z","timestamp":1622204371000},"page":"577-597","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis)"],"prefix":"10.1016","volume":"105","author":[{"given":"Cindy England","family":"Owen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ACI.0000000000000546","article-title":"Making a diagnosis in severe cutaneous drug hypersensitivity reactions","volume":"19","author":"Ardern-Jones","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib2","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.001_bib3","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaip.2018.08.013","article-title":"Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome identified in the electronic health record allergy module","volume":"7","author":"Wolfson","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.001_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/ajd.12085","article-title":"Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome","volume":"55","author":"Fernando","year":"2014","journal-title":"Australas J Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.001_bib6","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1365-2133.2007.07807.x","article-title":"The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations","volume":"156","author":"Shiohara","year":"2007","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.001_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MD.0b013e3181a4d1a1","article-title":"Drug-induced hypersensitivity syndrome","volume":"88","author":"Ben M'Rad","year":"2009","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0378-6323.74964","article-title":"Drug hypersensitivity syndrome","volume":"77","author":"Kumari","year":"2011","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.001_bib9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/1346-8138.14776","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs","volume":"46","author":"Tashiro","year":"2019","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.mcna.2021.04.001_bib10","first-page":"1","article-title":"Recent advances in drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms","volume":"2018","author":"Watanabe","year":"2018","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.mcna.2021.04.001_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.12659\/AJCR.907464","article-title":"Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to furosemide: case report and review of literature","volume":"19","author":"James","year":"2018","journal-title":"Am J Case Rep"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2019.02.002","article-title":"Vancomycin-associated drug-induced hypersensitivity syndrome","volume":"81","author":"Madigan","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.alit.2016.04.001","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS): 11 years retrospective study in Thailand","volume":"65","author":"Hiransuthikul","year":"2016","journal-title":"Allergol Int"},{"key":"10.1016\/j.mcna.2021.04.001_bib14","first-page":"3186328","article-title":"HLA association with drug-induced adverse reactions","volume":"2017","author":"Fan","year":"2017","journal-title":"J\u00a0Immunol Res"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.clindermatol.2019.10.015","article-title":"The life-threatening eruptions of immune checkpoint inhibitor therapy","volume":"38","author":"Coleman","year":"2020","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.001_bib16","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13183","article-title":"HLAs: key regulators of T-cell-mediated drug hypersensitivity","volume":"91","author":"Redwood","year":"2018","journal-title":"Hla"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"10.1016\/j.mcna.2021.04.001_bib19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1346-8138.2008.00548.x","article-title":"Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients","volume":"35","author":"Kashiwagi","year":"2008","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.001_bib20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2018.5360","article-title":"Evaluation of prospective HLA-B\u221713:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy","volume":"155","author":"Liu","year":"2019","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.001_bib21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"Hla"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaci.2019.01.045","article-title":"HLA-A\u221732:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms","volume":"144","author":"Konvinse","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.001_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.56.7.890","article-title":"TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients","volume":"56","author":"Pirmohamed","year":"2001","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.001_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/S0365-05962012000300013","article-title":"Drug reaction with Eosinophilia and Systemic Symptoms (DRESS)\/Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts","volume":"87","author":"Criado","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.001_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.clindermatol.2018.12.004","article-title":"The rash with maculopapules and fever in adults","volume":"37","author":"Muzumdar","year":"2019","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.mcna.2021.04.001_bib26","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.seizure.2019.07.015","article-title":"Rashes and other hypersensitivity reactions associated with antiepileptic drugs: a review of current literature","volume":"71","author":"Mani","year":"2019","journal-title":"Seizure"},{"issue":"8","key":"10.1016\/j.mcna.2021.04.001_bib27","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/TP.0000000000001655","article-title":"Acute liver failure\/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors","volume":"101","author":"Ichai","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.mcna.2021.04.001_bib28","first-page":"1503709","article-title":"Treatments for severe cutaneous adverse reactions","volume":"2017","author":"Cho","year":"2017","journal-title":"J\u00a0Immunol Res"},{"issue":"12","key":"10.1016\/j.mcna.2021.04.001_bib29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.001_bib30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/1346-8138.12770","article-title":"Sequelae in 145 patients with drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR)","volume":"42","author":"Kano","year":"2015","journal-title":"J\u00a0Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib32","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjd.15360","article-title":"Long-term complications of Stevens-Johnson syndrome\/toxic epidermal necrolysis (SJS\/TEN): the spectrum of chronic problems in patients who survive an episode of SJS\/TEN necessitates multidisciplinary follow-up","volume":"177","author":"Lee","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.mcna.2021.04.001_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40264-018-0711-x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case-control study","volume":"42","author":"Frey","year":"2019","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.mcna.2021.04.001_bib35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2021.04.001_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.eplepsyres.2017.05.015","article-title":"Association between the HLA-B alleles and carbamazepine-induced SJS\/TEN: a meta-analysis","volume":"135","author":"Wang","year":"2017","journal-title":"Epilepsy Res"},{"issue":"10106","key":"10.1016\/j.mcna.2021.04.001_bib37","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","article-title":"Severe cutaneous adverse reactions to drugs","volume":"390","author":"Duong","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.001_bib38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jaad.2019.05.061","article-title":"Distinguishing Stevens-Johnson syndrome\/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review","volume":"81","author":"Weinkle","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.001_bib39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clindermatol.2018.12.008","article-title":"The rash that presents as target lesions","volume":"37","author":"Wolf","year":"2019","journal-title":"Clin Dermatol"},{"issue":"6","key":"10.1016\/j.mcna.2021.04.001_bib40","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens-Johnson Syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.001_bib41","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/jbcr\/irx023","article-title":"Variability in management of patients with SJS\/TEN: a survey of burn unit directors","volume":"39","author":"Richard","year":"2018","journal-title":"J\u00a0Burn Care Res"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib43","doi-asserted-by":"crossref","first-page":"e12832","DOI":"10.1111\/dth.12832","article-title":"Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature","volume":"32","author":"Wang","year":"2019","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.001_bib44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.mcna.2021.04.001_bib45","first-page":"E17","article-title":"Cyclosporine in SJS\/TEN management: a brief review","volume":"97","author":"Shokeen","year":"2016","journal-title":"Cutis"},{"issue":"7","key":"10.1016\/j.mcna.2021.04.001_bib46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","volume":"43","author":"Chung","year":"2016","journal-title":"J\u00a0Dermatol"},{"issue":"9","key":"10.1016\/j.mcna.2021.04.001_bib47","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1111\/jdv.16137","article-title":"Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"34","author":"Torres-Navarro","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.001_bib48","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jaad.2015.07.017","article-title":"Acute generalized exanthematous pustulosis (AGEP): a review and update","volume":"73","author":"Szatkowski","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.mcna.2021.04.001_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17081214","article-title":"Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy","volume":"17","author":"Feldmeyer","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.001_bib50","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.4081\/dr.2018.7686","article-title":"Cephalexin-induced acute generalized exanthematous pustulosis","volume":"10","author":"DaCunha","year":"2018","journal-title":"Dermatol Rep"},{"issue":"4","key":"10.1016\/j.mcna.2021.04.001_bib51","doi-asserted-by":"crossref","first-page":"e12617","DOI":"10.1111\/dth.12617","article-title":"Acute generalized exanthematous pustulosis due to terbinafine","volume":"31","author":"Ross","year":"2018","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.001_bib52","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.001_bib53","first-page":"e22","article-title":"Acute generalized exanthematous pustulosis caused by pantoprazole","volume":"101","author":"Schmitz","year":"2018","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.mcna.2021.04.001_bib54","doi-asserted-by":"crossref","first-page":"e12660","DOI":"10.1111\/dth.12660","article-title":"Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine","volume":"31","author":"Castner","year":"2018","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.mcna.2021.04.001_bib55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000314474","article-title":"Acute generalized exanthematous pustulosis induced by cefepime: a case report","volume":"2","author":"Botelho","year":"2010","journal-title":"Case Rep Dermatol"},{"issue":"6\u20137","key":"10.1016\/j.mcna.2021.04.001_bib56","first-page":"612","article-title":"[Drugs associated with acute generalized exanthematic pustulosis]","volume":"130","author":"Saissi","year":"2003","journal-title":"Ann Dermatol Venereol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T23:23:24Z","timestamp":1710458604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712521000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0025712521000390"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2021.04.001","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis)","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2021.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}